ArticleNeurourology and urodynamics2026
Urodynamic and Anamnestic Predictors for Individual Dose Adjustment of Intravesical Oxybutynin in Neurogenic Detrusor Overactivity: Results From the UPSIDE Study.
Article in Neurourology and urodynamics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
introductionIntravesical oxybutynin (IVO) is a 2nd line treatment option for patients with neurogenic detrusor overactivity (NDO) who are not adequately managed by oral anticholinergics. The UPSIDE study aimed to identify urodynamic and anamnestic predictors for achieving a therapeutically satisfactory dose (TSD) of 1 mg/mL IVO and to evaluate treatment outcomes including continence, quality of life (QoL), adherence, and handling.
methodsUPSIDE was a prospective, multicentre, non-interventional, real-world study including paediatric (age ≥ 6) and adult patients with NDO due to spinal cord injury (SCI), spina bifida (SB), or multiple sclerosis (MS). Patients switched to IVO (VESOXX) were observed for at least 3 months. The primary endpoint was achievement of a TSD. Secondary endpoints included urodynamic changes, continence, spontaneous micturition, catheter volume, urinary tract infections (UTI), QoL (SF-Qualiveen-questionnaire), adherence, persistence, handling, pre- and concomitant therapies and safety.
resultsOf 54 patients enrolled across 14 study centres, 36 formed the full analysis set, and 26 (72%) were categorized with a TSD. Older age and reduced estimated glomerular filtration rate (eGFR) were identified as predictors for TSD (p = 0.059; p = 0.011, respectively). A dose adaptation was necessary for almost every second patient (47.2%). Urodynamic parameters such as p
conclusionVESOXX was effective in improving urodynamic parameters, continence, QoL, reduction of UTI and handling experience in NDO patients, with high adherence and no therapy-related serious adverse events. TSD prediction is associated with older age and reduced eGFR. UPSIDE provides clinically relevant guidance for individualized intravesical therapy; however, interpretation of pressure-based safety targets should remain cautious within the context of this pragmatic real-world study.
trial registrationThe UPSIDE non-interventional trial is registered in the German clinical study registry DRKS under the number: DRKS00028775.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.